PRELIMINARY PROGRAMME
& Call for abstracts

4th CONGRESS OF THE PSORIASIS INTERNATIONAL NETWORK

PSORIASIS 2013

4-6 JULY 2013
PALAIS DES CONGRÈS – PARIS – FRANCE

For more information please visit
www.pso2013.com
Email: pso2013@mci-group.com

Organised by the Fondation René Touraine
An international foundation for dermatology

Under the auspices of the EADV Psoriasis Taskforce
Table of Contents

• Welcome Address .......................................................... 3
• Committees .................................................................. 4
• Schedule at a glance .................................................... 5
• Abstracts submission & Programme ............................... 6
• General information & Conditions ................................ 15
• Registration procedure ................................................ 17
• Accommodation ............................................................ 18
• Acknowledgements ....................................................... 19

Key Dates to Remember

• Deadline for abstract submission for free communications and posters: February 15, 2013
• Advance registration deadline ..................................... March 20, 2013
• Deadline for hotel reservations .................................... May 4, 2013
• Opening on-site secretariat ............................................ July 4, 2013

Congress Office

• Scientific Secretariat, Registration, Accommodation, Exhibition, Sponsorship:
  PSORIASIS 2013 – MCI
  24 rue Chauchat – 75009 Paris – France
  Tel.: 33 (0) 1 53 85 82 59 – Fax: 33 (0) 1 53 85 82 83

• Email:
  - For general information: pso2013@mci-group.com
  - For registration and accommodation: pso2013REG@mci-group.com
  - For exhibition and sponsorship: pso2013EXH@mci-group.com
  - For Abstract submission: pso2013ABS@mci-group.com

• website: www.pso2013.com
Welcome address

Dear Colleagues and Friends,

On behalf of the Psoriasis International Network (PIN) of the Fondation René Touraine represented by professor Carle Paul and professor Luigi Naldi, it is our great pleasure to cordially invite you to participate in the 4th International Congress on Psoriasis. Psonet, responsible for the scientific coordination of the congress, is a well established network of psoriasis registries active in several European and Non-European countries, with the aim of promoting the comparison and combination of long term outcome data.

This congress series is directly aimed to serve the needs of practicing dermatologists involved in psoriasis care across countries in outpatient services, hospital settings, and private practice. Therefore, we have invited keynote speakers from all fields of psoriasis research and care, to give you an update on the latest developments in diagnosis and treatment of psoriasis, including comorbidities, and in difficult clinical scenarios that may arise during the long-term management, with a view on psoriasis as a complex chronic multifactorial inflammatory disease not limited to the skin. A perspective on evidence-based and personalised care, on Public Health issues, and on the collaboration to obtain a better safety profile of treatment options will be favoured.

Furthermore, fields such as patient education, psoriasis in children and pregnancy, topical treatment challenges, will be addressed in workshops which allow you to directly interact with internationally experienced speakers.

Make sure that you don’t miss this unique opportunity to update your knowledge on psoriasis, and take also the advantage to enjoy Paris at this wonderful time of the year!

Sincerely,

Carle Paul
Coordinator of the Psoriasis International Network

Louis Dubertret
President Board of Directors
Fondation René Touraine

Luigi Naldi
Coordinator of the scientific programme
Committees

SCIENTIFIC COORDINATION

Luigi NALDI
On behalf of PSONET, European network of psoriasis registries

Eugenia CAGGESE
Congress Secretary

GENERAL COORDINATION

PIN Committee of the Fondation René Touraine

Carle PAUL
President

Luigi NALDI
President Elect

PROGRAMME COMMITTEE

Members of the PSONET
www.psonet.eu

Members of the Scientific and Advisory Board of the Psoriasis International Network
www.psoriasis-international.org

NATIONAL COORDINATORS – PSORIASIS INTERNATIONAL NETWORK

AMMAR-KHODJA Aomar, Algeria
UBOGUI Javier, Argentina
CHOUELA Edgardo, Argentina
BRUNNER Patrick, Austria
ADASKEVICH Uladzimir, Belarus
DE LA BRASSINE Michel, Belgium
SEGAERT Sigfried, Belgium
DIEZ DE MEDINA Juan Carlos, Bolivia
AZULAY Luna, Brazil
SANTAMARIA Jesus, Brazil
TAKAHASHI Maria Denise, Brazil
TSANKOV Nikolai, Bulgaria
POULIN Yves, Canada
DE LA CRUZ Claudio, Chile
VALDES Pilar, Chile
RIVEROS Tatiana, Chile
ZHENG Min, China
LEE Chih-Hung, Chinese Taipei
GONZALEZ A. Cesar, Colombia
LONDONO Angela, Colombia
VARGAS Miriam, Colombia
ALVAREZ Laura, Costa Rica
CEOVIC Romana, Croatia
BLANCO G. Orestes, Cuba
PEREZ ALONSO Teresita, Cuba
RODRIGUEZ Roxana, Cuba
HERGOGOVA Jana, Czech Rep.
GNIADZEKI Robert, Denmark
ESPINAL Alexandro, Dominican Rep.
URAGA Enrique, Ecuador
LOAYZA Enriqde, Ecuador
BRIONES Maria Cecilia, Ecuador
ELGAMAL Emad, Egypt
QUINTANILLA Elena, El Salvador

MARTINEZ LOPEZ Jaime, El Salvador
KINGO Külli, Estonia
RANKI Annamari, Finland
BACHELEZ Hervé, France
PAUL Carle, France
CHHIJAVADZE Nino, Georgia
ANTONIOU Christina, Greece
BRAN QUINTANA Gerardo, Guatemala
RAMOS Liglia, Honduras
KEMENY Lajos, Hungary
OLAFSSON Jon Halla, Iceland
KUMAR A.S., India
WIRYADI Benny, Indonesia
ZARGARI Omid, Iran
DAVID Michael, Israel
PAVLOVSKY Lev, Israel
NALDI Luigi, Italy
NAKAGAWA Hidemi, Japan
MALEK M. Abdul, Jordan
YOUN Jai II, Korea
AL-MUTAIRI Nawaf, Kuwait
RUBINS Andris, Latvia
KIBBI Abdul-Ghani, Lebanon
VALIUKIJEVIĆE Skaidra, Lithuania
DUWEB Gamal A., Lybia
MANASIEVSKA Emiliya, Macedonia
SIEW ENG Choon, Malaysia
CHOONG CHOR Chang, Malaysia
BOFFA Michael, Malta
LEON Gladys, Mexico
NEDELICU Boris, Moldova
BENCHIKHI Hakima, Morocco
SPULS Pyllis, Netherlands
NEIRA Jorge, Nicaragua
OUNUNI Abel, Nigeria
KROGSTAD Anne-Lene, Norway
MASHAL Riad, Palestine
ALVARENGA DE M. Victoria, Paraguay
GUZMAN FAWCETT Antonio, Paraguay
CASTRO VARGAS Evelyn, Peru
DEL SOLAR Manuel, Peru
FREZ Maria Lorna, Philippines
SZPETOWSKI Jacek, Poland
FIGUEREDO Américo, Portugal
TIPICA George-Sorin, Romania
POTEKAEV Nikolay, Russia
BUKHARI Iqbal A., Saudi Arabia
LY Fatimata, Senegal
MEDENICA Lilijana, Serbia
THENG Colin, Singapore
URBANEC Slavomir, Slovakia
MILKOVIC Jovan, Slovenia
LUNDER Tomaz, Slovenia
PUIG Luis, Spain
STAHELE Mona, Sweden
YAWALKAR Nikki, Switzerland
HASSAN Fouz, Syria
DOSS Nijab, Tunisia
Gurer Mehmet Ali, Turkey
GRIFFITHS Christopher, UK
LITUS Oleksandr, Ukraine
CARMONA Carlos, Uruguay
MACEDO Nestor, Uruguay
LEBWOHL Mark, USA
PAEZ Erika, Venezuela
CABELLO Ismery, Venezuela
ROTHE Julia, Venezuela

There will be no further announcement before the meeting. For updates, information, registration, abstracts submission, questions, please visit the Congress website:

www.pso2013.com
Schedule at a glance

**THURSDAY, JULY 4**
- **REGISTRATION**
- IPC Meet the experts
- SY ABBVIE
- SY CELEGENE
- Break
- **PLENARY SESSION 1**
- WS 1
- WS 2
- WS 3
- **Networking Reception**

**FRIDAY, JULY 5**
- WS 4
- WS 5
- WS 6
- WS 6 bis
- Break
- **PLENARY SESSION 2**
- SY GENEVRIER/IBSA
- SY JANSSEN
- SY PFIZER
- Lunch break
- WS 7
- WS 8
- WS 9
- **PLENARY SESSION 4**
- SY MSD
- SY PFIZER
- SY NOVARTIS
- **National Coordinators Meeting**

**SATURDAY, JULY 6**
- WS 10
- WS 11
- WS 12
- Break
- **PLENARY SESSION 3**
- SY Lilly
- Lunch break
- WS 13
- WS 14
- WS 15
- WS 16

There will be in each session time for questions and answers.
Abstracts submission & Programme

The DEADLINE for ABSTRACTS submission is: February 15, 2013.
Please go to the website to read the guidelines and submit your abstract:

www.pso2013.com

All abstracts must be written in English. Selected abstracts will be presented as posters and the best scored posters will be presented during the workshop sessions.

Submission topics:

1. Scoring and monitoring the severity of the disease
2. Psoriasis in children and pregnancy
3. Psoriasis Arthritis
4. Comorbidities in Psoriasis
5. Psychological/Social impact of psoriasis
6. Psoriasis – pathogenesis
7. Clinical guidelines and recommendations for psoriasis treatment
8. Health economics of psoriasis
9. Patient education
10. Clinical trials in psoriasis
11. Epidemiology
12. Others

Remember that ONLY electronically submitted abstracts will be considered.
Thursday 4th July 2013

10:00-12:00
IPC Meet the experts – A case-based Learning Discussion

12:00-13:30
SY Satellite Symposium ABBVIE
Satellite Symposium CELGENE

14:00-16:00
PS1 Plenary Session 1
O001 Welcome Lecture: The Psonet collaboration
   Luigi Naldi
   Chair and Discussant: Erwin Tschachler

Psoriasis management: targeting the patient
Chairs: Mehmet Ali Gürer, Julia Rothe, Patrick Brunner
O002 • Psoriasis at the origin of the patient-based medicine
   Louis Dubertret
O003 • Evaluation of severity and treatment goals
   Tamar Njisten
O004 • Evidence based medicine and personalized treatment
   Olivier Chosidow
O005 • Patient impact on treatment choices
   Uwe Gieler

16:30-18:00
WS1 Workshop 1
Clinical guidelines and recommendations for psoriasis treatment
Chairs: Nejib Doss, Colin Theng, Gladys Leon
O021 • The methodology of developing guidelines
   Catherine Smith
O022 • Guidelines around the world: a critical overview
   Phyllis Spuls
O023 • The implementation of guidelines: effect of health authorities,
   and reimbursement bodies
   Alexander Nast
O024 • Side effects of guidelines
   Chris Baker

P001 ANTIBODY FORMATION TO ADA LUMAB IN THE TREATMENT OF PSORIASIS VULGARIS IS MOST OFTEN SEEN BEFORE
24 WEEKS OF TREATMENT AND HAS GREAT INFLUENCE ON CLINICAL EFFICACY: ONE YEAR DATA IN 59 PATIENTS
S. Menting*, P. V. Lumig, A.-C. D. Vries, G.-J. Wolbink, E. D. Jong, P. Spuls, L. Lecluse
P002 CLINICAL EXPERIENCE OF USTEKINUMAB FOR THE TREATMENT OF ELDERLY PATIENTS WITH PSORIASIS
M. Hayashi, U. Yoshinori, M. Yasuda, O. Fukuchi, T. Ito, H. Saeki, H. Nakagawa
16:30-18:00

WS2 Workshop 2

Complicated scenarios

Chairs: Andrew Finlay, Claudia de la Cruz, Abdul-Ghani Kibbi

O025 • Managing psoriasis in cancer patients
Myrto Trakatelli

O026 • Managing psoriasis in patients with chronic hepatitis
Van Voorhees

O027 • Managing psoriasis in HIV and immuno-compromised patients
Martine Bagot

O028 • Drug associations and interactions
Michael David

P004 THE CARDIOVASCULAR ASSESSMENT TOOL (CVAT): ASSESSING RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH FUMARIC ACID ESTERS
K. Reich*, K. Merten, N. Berenzen, W.-H. Boehncke

P005 PSORIATIS IS NOT ASSOCIATED WITH Atherosclerosis and incident cardiovasCULAR EVENTS: THE ROTTERTaM STUDY

P006 INSOMNIA IN PATIENTS WITH PSORIASIS: CONSEQUENCES AND ASSOCIATED FACTORS

16:30-18:00

WS3 Workshop 3

Looking at the future

Chairs: Carlo Pincelli, Chih-Hung Lee, Külli Kingo

O029 • Pharmacogenetics: what could we expect for the near future?
Alexander Navarini

O030 • Phenotyping and genotyping
Tsen-Fang Tsai

O031 • Personalised medicine and psoriasis
Frank Nestle

O032 • Can progression of psoriasis be prevented?
Junko Takeshita

P007 IMPAIRED NUCLEAR TRANSLLOCATION OF GLUCOCORTICOID RECEPTORS: NOVEL FINDINGS FROM PSORIATIC EPidermal Keratinocytes
M. Zheng*, X. Man

P008 PSORiATiS SkIN MOdel PRODUCED BY THE AUTO-ASSEMBLY METHOD: EVALUATION OF NEW ALTERNATiVES
I. Gendreau*, J. Jean, R. Pouliot

P009 CHARACTERIZATION OF PSORiATiS SkIN SUBSTITUTES CULTURED IN SERUM OR SERUM-FREE CONDITION AT THE AIR-LIQUiD INTERFACE
8:30-10:00

**WS4 Workshop 4**

**Psoriatic arthritis**
Chairs: Philip Helliwell, Vito Di Lernia, Alice Gottlieb

- **O033** The diagnosis of psoriatic arthritis
  Philip Helliwell

- **O034** Severity assessment of psoriatic arthritis
  Oliver Fitzgerald

- **O035** Mild arthritis: a therapeutic challenge
  Piercarlo Sarzi Puttini

- **O036** Clinical guidelines for the management of psoriatic arthritis
  Olivier Fitzgerald

**P010**
THE PREDICTIVE FACTORS OF ADVERSE EVENTS IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH ANTI-TNF DRUGS
F. Atzeni *, C. Ricci, D. Ventura, R. Caporali, L. Cavagna, F. Saccardo, R. Pellerito, R. Gorla, A. Marchesoni, P. Sarzi-Puttini

**P011**
ELBOW ARTHRITIS AND PALMOPRANT PUSTULOSIS: IS IT PSORIATIC ARTHRITIS OR SAPHO SYNDROME?
A. Souissi *, I. Gharsallah, B. Tazzayt, L. Metoui, B. Louzir, S. Othmani

**P012**
APREMILAST: POOLED SAFETY ANALYSIS OF THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS

8:30-10:00

**WS5 Workshop 5**

**Health economics of psoriasis**
Chairs: Matthias Augustin, Robert Stern, Marcus Schmitt Egenolf

- **O037** Health economics: definitions
  Speaker to be confirmed

- **O038** The cost of psoriasis in Europe
  Livio Garattini

- **O039** The cost of psoriasis in USA
  April W. Armstrong

- **O040** Cost-effectiveness analysis of psoriasis management
  Matthias Augustin

**P013**
QUALITY OF LIFE AND HEALTH-STATE UTILITIES IN PSORIASIS PATIENTS AT THE NATIONAL SKIN CENTRE, SINGAPORE
J. Y. Pan* and National Skin Centre
8:30-10:00

**WS6 Workshop 6**

**Patient education**

Chairs: Maria Lorna Frez, Tsira Leonidze, Fatimata Ly

- **O041** The cumulative life course impairment
  Andrew Finlay

- **O042** Coping – a strategic issue
  Ray Jobling

- **O043** Health education: what it is all about
  Dennis Linder

- **O044** Compliance in psoriasis
  Peter van de Kerkhof

---

**P014** PATIENT TRAINING FOR PSORIASIS – EVALUATION OF A STANDARDIZED PROGRAM
H. Kling, J. Jahn, M. Sticherling*

**P015** PREVALENCE OF NEGATIVE FEELINGS AND MISCONCEPTIONS ABOUT PSORIASIS IN FRENCH POPULATION

8:30-10:00

**WS6 Workshop 6 bis** sponsored by Pfizer

**The relevance of immunogenicity in the treatment of psoriasis**

Chairs: Alexander Navarini, George Sorin Tiplica

- **O045** Classification of psoriasis gene expression patterns. Any use for predicting treatment response?
  Frank Nestle

- **O046** Immunologic responses in psoriasis patients treated by biological agents. How frequently anti-drug antibodies develop and their clinical relevance
  Denis Jullien

- **O047** Immunogenicity of anti-TNF biologic therapies in rheumatologic conditions
  Gert-jan Wolbink

---

10:30-12:30

**PS2 Plenary Session 2**

- **O006** Keynote Lecture: Health care for psoriasis in Europe: a lesson for the future
  Matthias Augustin
  Chair and Discussant: Caius Solovan

**Psoriasis a lifelong disease**

Chairs: AJ Kanwar, Aomar Ammar-Khodja, Skaidra Valiukeviciene

- **O007** Maintaining treatment after clearance: the evidence
  Jonathan Barker

- **O008** Chronic inflammation and metabolic syndrome: a link? Pros and Cons
  Sinead Langan

- **O009** Comorbidities impacting treatment choice
  Carle Paul

- **O010** A treatment for life: what are the limits of existing therapies
  Robert Stern
12:30-14:30  LUNCH BREAK

12:45-14:15

SY Satellite Symposium GENEVRIER/IBSA
JANSSEN sponsored Satellite Symposium
PFIZER sponsored Satellite Symposium

14:30-16:00

WS7 Workshop 7
Psoriasis registries
Chairs: Alexa Kimball, Roshidah Baba, Thomas Diepgen

O048  • What registries can and cannot do
       Kathleen Mc Ethone
O049  • Why and how to make a registry
       Arnon Cohen
O050  • Overview of publications from registries
       Tony Ormerod
O051  • The future of registries in psoriasis
       Marcus Schmitt Egenolf

P016  SERIOUS INFECTION EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY: CURRENT STATUS OF
       OBSERVATIONS
       C. Leonardi, D. Fiorentino, R. Kalb, M. Chevrier* and on behalf of the PSOLAR Steering Committee

P017  MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY:
       CURRENT STATUS OF OBSERVATIONS
       L. Naldi*, A. B. Gottlieb, F. Kerdel, R. Bissonnette, S. Faikharzadeh, S. Calabro, W. Langhoff, M. Chevrier and on behalf of the
       PSOLAR Steering Committee

P018  PSOLAR: GLOBAL UPDATE OF A MULTICENTRE, OPEN REGISTRY OF PSORIASIS PATIENTS
       K. Papp*, M. Augustin, B. Struber, V. Hlo, C. Binder, S. Calabro, W. Langhoff, M. Chevrier and on behalf of the PSOLAR Steering Committee

14:30-16:00

WS8 Workshop 8
Psoriasis in children, pregnancy and lactation
Chairs: Romana Ceovic, Laura Alvarez-Morales, Gudula Kirtschig

O052  • Pattern presentations of psoriasis in childhood
       Alur S. Kumar
O053  • Treatment options for managing moderate to severe psoriasis in childhood
       Maria Salavastru
O054  • Psoriasis and pregnancy: what the impact and what the treatment
       Nick Reynolds
O055  • Pregnancy occurring during systemic treatment for psoriasis: how to manage
       Edgardo Chouela

P019  CHILDHOOD ONSET PSORIASIS AND ITS DURATION: ASSOCIATION WITH FUTURE CARDIOVASCULAR AND METABOLIC
       COMORBIDITIES
       Steiner, C. Pauwels, M. Avenel-Audran, C. Goujon-Henry, V. Descamps, E. Begon, M.-L. Sigal and GEM RESOPS

P020  PSORIASIS FROM OR PSORIASIC ACRAL DERMATITIS AMONG 43 CASES OF PEDIATRIC PSORIASIS
       Ammorkhodja, A. Aitbenamar, A. Djoudi

P021  CHILDHOOD PSORIASIS: A RETROSPECTIVE STUDY OF 174 CASES.
14:30-16:00

**WS9 Workshop 9** sponsored by Lilly

**Drugs in the pipeline**

Chairs: Matilda Bylaitė, Lev Pavlovsky, Jovan Miljkovic

- **O056** Upcoming new biologics
  Neil Shear

- **O057** Biosimilars: is it all the same?
  Robert Gniadecki

- **O058** New small molecules, not only biologics: expected place in therapy
  Kristian Reich

- **O059** Issues for drug development in psoriasis
  Antonio Costanzo

**P022** EARLY CLINICAL RESPONSE PREDICTS SUBSEQUENT RESPONSE IN THE TREATMENT OF MODERATE TO SEVERE PLACQUE PSORIASIS IN A PHASE 2 TRIAL WITH IXEKIZUMAB (LY2439821)

B. Zhu, E. Edson-Heredia*, G. Cameron, W. Shen, J. S. Erickson, D. Shrom, S. Banerjee

**P023** EFFICACY OF AGANIRSEN, AN INSULIN RECEPTOR SUBSTRATE-1 ANTISENSE Oligonucleotide, IN THE TREATMENT OF MILD TO MODERATE PLACQUE PSORIASIS: A RANDOMISED, DOUBLE BLIND EXPLORATORY STUDY


16:30-18:00

**SY** MSD sponsored Scientific Satellite Symposium

**PFIZER** sponsored Satellite Symposium

**NOVARTIS** sponsored Satellite Symposium

18:00 -19:30

National Coordinators Meeting
Saturday 6th July 2013

8:30-10:00

**WS10 Workshop 10** sponsored by Lilly

**Biologics**
Chair: Chris Baker, Craig Leonard, Arnon Cohen

- O060  Antagonists of TNF alpha  Jörg Prinz
- O061  Antagonists of IL12-23 and IL 23  Kim Papp
- O062  Antagonists of IL17  Craig Leonard
- O063  Shifting and combining in the biological era  Otsuki Mamitaro

**P024** PARADOXICAL PSORIASIS INDUCED BY TUMOR NECROSIS FACTOR-ALPHA: OUR EXPERIENCE
S. Pérez-Barrío*, M. L. García-Vivar, E. Galíndez, L. Blanch, J. González de Tárano, S. Gómez, J. M. Careaga

**P025** EVALUATION OF THE IMPACT OF BODY WEIGHT ON THE EFFICACY OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS: A DOSE-RESPONSE META-ANALYSIS
J. Mandema, M. Peterson, S. Ahadieh, H. Tan, S. Krishnaswami, R. Wolk, P. Gupta*

8:30-10:00

**WS11 Workshop 11**

**Epidemiology meets practice in psoriasis management**
Chairs: Francesco Cusano, Fouz Hassan, Ignacio Garcia Doval

- O064  Lifetime incidence and mortality of psoriasis  Wayne Gulliver
- O065  Risk factors and triggers  Abrar Qureshi
- O066  Methodology of phenotyping psoriasis  Christiane Guinot
- O067  Long term outcomes in psoriasis  Alexa Kimball

**P026** PATIENT REPORTED PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH IN PSORIASIS

**P027** BIOLOGIC THERAPIES IN THE TREATMENT OF PSORIASIS: THEIR ASSOCIATION WITH THE DEVELOPMENT OF SPECIFIC INFLAMMATORY COMORBID CONDITIONS AMONG A COHORT OF THE NEWFOUNDLAND AND LABRADOR POPULATION
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald

**P028** RISK OF DEVELOPING CANCER AMONG PSORIASIS PATIENTS AS COMPARED TO NON-PSORIASIS PATIENTS.
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald
8:30-10:00

**Workshop 12**

How would I treat it?

Chairs: Giampiero Girolomoni, Benny Wiryadi, Phyllis Spuls

- O068  Psoriasis limited to the nails: how to diagnose, assess severity and how to treat it
  - Andreas Katsambas

- O069  Treating itch in psoriasis
  - Jacek Szepietowski

- O070  Pustular and erythrodermic psoriasis: how to manage
  - Luis Puig

- O071  Palmoplantar pustulosis: is it psoriasis? How to treat it
  - Joanna Narbutt

---

10:30-12:30

**Plenary Session 3**

- O011  Keynote Lecture: How to assess the safety of psoriasis drugs
  - Hervé Bachelez
  - Chair and Discussant: Joel Gelfand

Specific aspects of psoriasis management

Chairs: Jesús Santamaría, Amerigo Figueiredo, Mara Maccarone

- O012  Emergencies in psoriasis management
  - Esteban Dauden

- O013  Mild psoriasis: a therapeutic challenge
  - Wolfram Sterry

- O014  Psoriasis in children
  - Christine Bodemer

- O015  Psoriasis arthritis
  - Alice Gottlieb

12:30-14:00  LUNCh BREAK

**Satellite Symposium LILLY**
14:00-16:00

**Plenary Session 4**

O016  
**Keynote Lecture: Shifting paradigm in pathophysiology of psoriasis**  
Thomas Luger  
Chair and Discussant: Alice Gottlieb

**Optimal use of conventional systemic treatment**  
Chairs: Omid Zargari, Nino Chijavadze, Luca Borradori

- O017  
  Calcineurin inhibitor  
  Stefano Piaserico

- O018  
  Methotrexate  
  Richard Warren

- O019  
  Fumaric acid esters  
  Sandra Philipp

- O020  
  Acitretin  
  Jana Hercogova

16:30-18:00

**Workshop 13**

**Advancements in phototherapy**  
Chairs: Nikolai Tsankov, Nawaf Al-Mutairi, Iqbal A. Bukhari

- O072  
  NBUVB and PUVA therapy  
  Giovanni Leone

- O073  
  Home UV treatment  
  José Manuel Carrascosa

- O074  
  Excimer laser  
  Klaus Fritz

- O075  
  Combination therapies  
  Piergiacomo Calzavara-Pinton

P032  
**EFFICACY, SAFETY AND DOSAGE OF FUMARIC ACID ESTERS IN COMBINATION WITH PHOTOTHERAPY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS**  
K. Reich*, B. Braeu, K. Merten, W. Grienberg

P033  
**IS BASIC FIBROBLAST GROWTH FACTOR A MEDIATOR THROUGH WHICH ULTRAVIOLET RADIATION INDUCES FOXP3+ REGULATORY T CELLS IN PSORIASIS?**  
L. Chen, X. Yang, Z. Shen*

P034  
**COMBINED CLIMATOTHERAPY ON THE BLACK SEA COMPARED TO NARROW BAND UVB THERAPY FOR TREATMENT OF PSORIASIS**  
I. Bogdanov*, N. Tsankov
16:30-18:00

**WS14 Workshop 14**

**Triggering psoriasis: recent developments in understanding mechanisms**

Chairs: Enno Christophers, Erika Paes, Gamal Duweb

- **O076** Biology of the Koebner phenomenon
  Georg Stingl

- **O077** Adipose tissue and inflammation
  Paolo Gisondi

- **O078** Is there any role for medications in triggering psoriasis?
  Yves Poulin

- **O079** Infections and psoriasis triggering: myths and facts
  George Sorin Tiplica

**P035** EVALUATION OF RISK FACTORS FOR BODY WEIGHT GAIN IN PSORIATIC PATIENTS ON INFlixImAB: A MULTICENTRE, CROSS-SECTIONAL STUDY

**P036** “PRO-OSTEOCLASTOGENESIS MARCH” IS INDUCED BY CUTANEOUS PRO-INFLAMMATORY MEDIATORS
  A. Raimondo*, F. Ayala, R. Di Caprio, S. Lembo, M. Matti, M. Schiattarella, N. Balato, A. Balato

**P037** RELATIONSHIP BETWEEN MALE-FEMALE RATIO AND BODY MASS INDEX IN PSORIASIS IN JAPAN
  R. Naito*, S. Imafuku, T. Tokunaga, K. Sasamoto, M. Koga, J. Nakayama

16:30-18:00

**WS15 Workshop 15**

**Psoriasis and global health**

Chairs: Emad Elgamal, Louis Dubertret

- **O080** Variations in management of psoriasis in Europe
  Ignacio García Doval

- **O081** Why do patients stop their psoriasis treatment: the US perspective
  Joel Gelfand

- **O082** Managing psoriasis in patients with less resources
  Nejib Doss

- **O083** Networking in psoriasis: the example of the Euro-Asian interaction
  Oleksandr Litus

**P038** CLINICAL CHARACTERISTICS OF PATIENTS WITH FACIAL PSORIASIS IN MALAYSIA
  A. Mohd Affandi*, F. A. Alias, T. H. Ahmad, R. Babu

**P039** DERMATOLOGISTS’ PRACTICES AND ATTITUDES TOWARDS THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS IN RIYADH CITY, SAUDI ARABIA
  M. A. Atwa*, L. Fiola

**P040** DEPRESSION BURDEN IN PSORIASIS: A MOROCCAN STUDY
  H. Benhiba*, N. Guerrouaz, K. Jouidi, H. Syrine, K. Senouci, B. Lazia, B. Hassam
16:30-18:00  
**WS16 Workshop 16**  
**Topical treatment challenges**  
Chairs: Slavomir Urbancek, Uladzimir Adaskevich, Luigi Naldi  

- **O084**  
  The optimal use of anthralin  
  Lajos Kemeny

- **O085**  
  Difficult localization: scalp, face, genital area and flexural areas  
  Yoshinori Umezawa

- **O086**  
  Palmo plantar psoriasis  
  Min Zheng

- **O087**  
  Combination treatment  
  Cesar Gonzalez

**P041**  
NARROW BAND UVB MONOTHERAPY VERSUS TOPICAL CALCIPOTRIOL OINTMENT COMBINED WITH NARROW BAND UVB PHOTOTHERAPY FOR TREATMENT OF PSORIASIS VULGARIS  
N. A. Elsherif*, I. Elmangush, S. Eldibany
**ABSTRACTS**

**Posters presentations**

**P042** ANTI-TNF-ALPHA NEUTRALIZING ACTIVITY OF PATIENTS’ SERA EVALUATED WITH A NOVEL INTERLEUKIN (IL)-8 REPORTER CELL LINE CORRELATES WITH THE CLINICAL RESPONSE TO ANTI-TNF-ALPHA ANTIBODY

**P043** MANAGEMENT OF PLAQUE-TYPE PSORIASIS IN THE ADULT: THE ITALIAN NATIONAL CLINICAL GUIDELINES (ED. 2013)

**P044** INCREASING THE INJECTION INTERVALS OF ADA LIMUMAB IN PSORIATI C PATIENTS
O. Fukuchi*, T. Ito, Y. Umezawa, H. Saeki, H. Nakagawa

**P045** THE USE OF SPA IN PSORIASIS: A MOROCCAN EXPERIENCE
N. El Moussaoui*, S. Hamada, A. Abdou, N. Ismaili, L. Benzekri, M. Ait Ourhoui, K. Senouci, B. Hassam

**P046** INSUFFICIENT TETANUS VACCINATION STATUS IN PATIENTS WITH PSORIASIS AND SYSTEMIC IMMUNOSUPPRESSION
A. Koerber*, L. Leister

**P047** ONE UNUSUAL CASE OF PSORIASIS TONGUE RESISTANT TO ANTI TNF ALFA
C. Y. Sabbag*

**P048** A PHASE II STUDY OF PONESIMOD IN CHRONIC PLAQUE PSORIASIS: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES
L. Kemény*, R. Yankova, M. Talamonti, A. Vaclavkova, M. Burcklen, G. Thomas, D. D’Ambrosio

**P049** CLINICAL PHARMACOLOGY OF ANTI-IL-17 RECEPTOR ANTIBODY KHK4827 (BRODALUMAB) IN JAPANESE HEALTHY VOLUNTEERS AND SUBJECTS WITH MODERATE TO SEVERE PSORIASIS: A RANDOMIZED, DOSE-ESCALATION, PLACEBO-CONTROLLED STUDY
O. Nemoto*, H. Nagashima, K. Sayama, H. Kobayashi

**P050** A PHASE II STUDY OF PONESIMOD, AN ORAL, SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 MODULATOR, IN CHRONIC PLAQUE PSORIASIS
S. Chimenti*, P. Arenberger, S. Karpati, P.-G. Sator, A. Vaclavkova, M. Burcklen, M. Stefani, D. D’Ambrosio

**P052** APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: 16-WEEK RESULTS OF A PHASE III, RANDOMIZED, CONTROLLED TRIAL (ESTEEM I)

**P053** TOFA CINTIB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: 24-WEEK PRELIMINARY ANALYSIS FROM THE 56-WEEK PHASE 3 OPT RE-TREATMENT STUDY

**P054** Efficacy of Biologics for the Difficult to Treat Psoriatic Lesions
T. Ito*, H. Saeki, O. Fukuchi, Y. Umezawa, M. Hayashi, R. Yamane, H. Nakagawa

**P055** MALIGNANCY EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY: CURRENT STATUS OF OBSERVATIONS
R. Langley, B. Strober, M. Lebwohl, D. Fiorentino, S. Fakharzadeh*, S. Calabro, W. Langholff, M. Chevrier and on behalf of the PSOLAR Steering Committee

**P056** EFFICACY AND SAFETY OF SYSTEMIC METHOTREXATE VERSUS ACITRETIN IN PSORIASIS PATIENTS WITH SIGNIFICANT PALMOPLANTAR INVOLVEMENT: A PROSPECTIVE, RANDOMIZED STUDY
A. J. Kanwar*, A. Janagond

**P057** EFFECT OF GRANULOCYTE AND MONOCYTE ADSORPTION APERHESIS (GCAP) FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS: RESULTS FROM MULTICENTER STUDY IN JAPAN
S. Ikeda* and G-1 Study group

**P058** POWER DOPPLER ULTRASONOGRAPHY IN INTERDISCIPLINARY PRACTICE OF PATIENTS WITH PSORIASIS
A PASI \(\geq 90\) RESPONSE IS ASSOCIATED WITH IMPROVED PATIENT REPORTED OUTCOMES: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH PSORIASIS TREATED WITH IXEKIZUMAB


PATIENT REPORTED OUTCOMES AFTER 16 WEEKS TREATMENT WITH SUBCUTANEOUS IXEKIZUMAB IN A PHASE 2 TRIAL IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

C. Zachariae, E. Edson-Heredia*, J. S. Erickson, G. Cameron, B. Zhu, R. Matheson

USE OF INFLIXIMAB IN 25 LIBYAN PSORIASIS VULGARIS PATIENTS

A. Altrabulsy, A. H. Griew, E. M. Elmangoush, G. A. Duweb*

ETANERCEPT THERAPY PROVIDES RAPID RELIEF OF PSORIASIS SYMPTOMS IN PATIENTS OF LATIN AMERICA, EASTERN EUROPE, AND ASIA


TREATMENT SATISFACTION AMONG PATIENTS WITH PSORIASIS WHO WERE TREATED WITH 2 DIFFERENT DOSE REGIMENS OF ETANERCEPT: RESULTS FROM THE PRISTINE STUDY

W.-R. Lee, J.-I. Youn, P. Allmeyer, L. Malbris, J. Fuiman, R. Pedersen, R. Bogg*

STUDY DESIGN AND BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADAлимУМAB VERSUS METHOTREXATE TREATMENT IN PEDIATRIC PATIENTS WITH CHRONIC PLAQUE PSORIASIS

K. Papp*, D. Thaci, I. Landells, K. Unnebrink, D. A. Williams

BROAD BAND UVB VERSUS PAINT PUVA FOR PALMOPLANTAR PSORIASIS

A. Lozinski*, F. Pavlotsky, A. Barzilai

COMBINATION THERAPY OF BIOLOGICS WITH DEAD SEA CLIMATOTHERAPY IN PSORIASIS

M. Harari*, T. Ruzicka on behalf of RIDS, the Research Institute on Skin Diseases at the Dead Sea, A. Ingber on behalf of RIDS, Research Institute on Skin Diseases at the Dead Sea and RIDS, the Research Institute on Skin Diseases at the Dead Sea

NATURAL PHOTOTHERAPY OF PSORIASIS AT THE DEAD SEA IN JORDAN

Z. Z. Bisharat*

SUBCLINICAL ATHEROSCLEROSIS, VASCULAR DYSFUNCTION AND ABNORMAL LV MYOCARDIAL DEFORMATION IS SIMILAR BETWEEN PATIENTS WITH PSORIASIS AND NO HYPERTENSION AND PATIENTS WITHUNTREATED HYPERTENSION


RELATIONSHIP BETWEEN BODY MASS INDEX AND ACTIVITY OF PSORIASIS. PSO-RISK STUDY


ADIPONECTIN RECEPTOR EXPRESSION IN KERATINOCYTES OF PSORIASIS PATIENTS WITH RESPECT TO METABOLIC SYNDROME

S. Madanagobalane*, V. Sandhya, S. Anandan, S. Rao

AUTOIMMUNE THYROID DISORDERS IN PATIENTS WITH PSORIASIS

Ü. Gül*, M. Gönül

SUBCLINICAL ATHEROSCLEROSIS, VASCULAR DYSFUNCTION AND ABNORMAL LV MYOCARDIAL DEFORMATION IS SIMILAR BETWEEN PATIENTS WITH PSORIASIS AND NO HYPERTENSION AND PATIENTS WITHUNTREATED HYPERTENSION


CARDIOVASCULAR DISEASE RISK PROFILE IN PSORIASIS PATIENTS WITH AND WITHOUT TREATMENT RESPONSE IN THE PRISTINE STUDY

B. Kirby, U. Mrowietz, A. Szumski, H. Jones, L. Malbris*

PREVALENCE OF MAJOR CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS UNDER SYSTEMIC THERAPY IN SPAIN. PSO-RISK STUDY


TUBERCULOSIS, AN INDEPENDENT RISK FACTOR FOR PSORIASIS, OR A BINOMIAL RELATIONSHIP? RETROSPECTIVE CASE CONTROL STUDIES

L. Foia*, A. E Chiriac, V. Toma, F. Filip, A. Chiriac, C. Solovan
P076 VITAMIN D STATUS IN PATIENTS WITH PSORIASIS AND RHEUMATOID ARTHRITIS; ASSOCIATION WITH DISEASE ACTIVITY AND SERUM LEVEL OF TNF-α
M. A. Atwa*, M. Balata, N. Abdelrahman, A. Hussein, H. Kareem

P077 ASSOCIATION BETWEEN THE APOLIPOPROTEIN E (APOE) GENE POLYMORPHISM, THE SERUM APOE AND THE METABOLIC SYNDROME WITH PSORIASIS
R. Abdel Hay*, T. Lehtela, N. Ragab, L. Rashed

P078 REPORT OF THE PREVALENCE OF METABOLIC SYNDROME IN CROATIAN PSORIASIS PATIENTS
G. Krnjevic Peciz*, L. Tomic Babic, R. Ceovic, K. Kostovic, E. Lazic Mosler

P079 PSORIASIS AND COMORBIDITIES IN TUNISIAN POPULATION
M. Benelkahla, L. Boussofara*, A. Aounallah, M. Ben Moussa, N. Ghariani, W. Saidi, M. Denguezli, C. Belajouza, R. Nouira

P080 FATAL ACUTE RESPIRATORY DISTRESS COMPLICATING GENERALIZED PUSTULAR PSORIASIS
M. Laarif, L. Boussofara*, N. Ghariani, W. Saidi, A. Aounallah, M. Denguezli, C. Belajouza, R. Nouira

P081 A NOVEL SYSTEM FOR ESTIMATING THE METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS
O. Andreevskaia*, M. De La Brassinne, O. Vanhooteghem

P082 UNDERDIAGNOSIS OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS UNDER SYSTEMIC THERAPY IN SPAIN. PSO-RISK STUDY

P083 LIPID DISTURBANCES IN PSORIASIS PATIENTS WITH EXCESSIVE BODY MASS AND OF OBESITY
E. Topychkanova*, N. Filimonkova, N. Kiselyeva

P084 PSORIASIS COMORBIDITIES: MOROCCAN EXPERIENCE
H. Boudhir*, I. Ramli, M. Maellainin, K. Senouci, B. Hassam

P085 PERIPHERAL VASCULAR DISEASE AND CORONARY DISEASE IN PATIENT WITH PSORIASIS
M. L. Galimberti*, C. L. Anselmi, W. M. Masson Juarez, A. Cagide, E. Soriano, R. L. Galimberti

P086 CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SEVERE PSORIASIS: ARE THEY BEING WELL SCREENED AND TREATED? A REAL-WORLD SETTING STUDY
T. Torres*, R. Sales, J. P. Ferreira, C. Carvalho, C. Vasconcelos, B. da Silva, M. Selores

P087 A CASE OF SUB ACUTE THYROIDITIS IN A PATIENT ON ADALIMUMAB FOR TREATMENT OF REFRACTORY PALMO-PLANTAR PSORIASIS
A. Chiriac*, L. Foia, A. E. Chiriac, C. Solovan

P088 PREVALENCE OF METABOLIC SYNDROME AMONG ADULT FILIPINO PSORIASIS PATIENTS

P089 PSORIASIS IN A PATIENT WITH PALMOPLANTAR ECZEMA : A CHALLENGING DIAGNOSIS
S. Ben Taazayet*, K. Jaber, A. Souissi, S. Youssef, M. R. Dhaouia, N. Doss

P090 PROBLEMS OF THE PSORIASIS, ASSOCIATED WITH VIRUSES OF HERPES SIMPLEX
H. Astsaturov*, O. Syzon

P091 SHOULD WE CONSIDER DIFFERENT TREATMENT GOALS FOR CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS?
T. Torres*, R. Sales, J. P. Ferreira, C. Carvalho, C. Vasconcelos, B. da Silva, M. Selores

P092 PSORIASIS TIED TO HIGHER RISK OF DIABETES IN MOROCCAN PATIENTS
H. Benhiba*, F. El Amrani, K. Jouid, B. Hassam

P093 PROBLEMS OF THE PSORIASIS, ASSOCIATED WITH VIRUSES OF HERPES SIMPLEX
H. Astsaturov*, O. Syzon

P094 PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS IN A DERMATOLOGY DEPARTMENT IN ALGIERS
H. Sahel* and R. Belaoudmou, F. Hamchaoui, F. Otsmane, B. Bouadjar

P095 PSORIASIS AND COMORBIDITIES, A STUDY OF 77 TUNISIAN PATIENTS
A. Zaouak*, R. Bennously, H. Hammami, T. Badri, S. Fenniche, I. Mokhtar

P096 CO-EXISTING OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
M. A. Muttardi*, N. A. Elsherif, A. S. Eldahumi, I. M. Elmanush

P097 SOME DATA FROM THE EPIDEMIOLOGICAL SURVEY OF PSORIASIS IN GEORGIA
N. Chijavadze*, K. Tsgareishvili
P098 LOW TREATMENT SATISFACTIONS AMONG MODERATE TO SEVERE PSORIASIS PATIENTS TREATED WITH CONVENTIONAL THERAPIES
Q. Ding, T. Fan*

P099 SOCIODEMOGRAPHIC AND CLINICAL FEATURES OF PSORIASIS PATIENTS FROM THE SOUTHERN TURKEY
E. Alper*, B. Özkessici, B. Nazlim, E. Ergün, S. Koc, A. Akman-Karaka, E. Yılmaz

P100 PSORIASIS: WHICH MODE OF INHERITANCE FOR A COMMON DISEASE?
S. Marrakchi*, A. Masmoudi, M. Mseddi, S. Boudaya, H. Turki

P101 AN EXAMINATION OF BIOLOGIC TREATMENT GROUPS OF PSORIASIS PATIENTS IN A COHORT OF THE NEWFOUNDLAND AND LABRADOR POPULATION
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald, R. Aleghehbandan, J. Dowden

P102 PSORIASIS OF EARLY AND LATE ONSET IN TUNISIAN POPULATION
N. Litaieim, K. Jaber, J. El Khalifa, W. Kaabi, S. Youssef, M. R. Dhaoui, N. Doss*

P103 PREVALENCE OF ONYCHOMYCOSIS IN PATIENTS WITH NAIL PSORIASIS
H. Boudhiri*, M. Mael Ainin, I. Ramli, M. Ait Ouirroui, B. Hassam

P104 CHARACTERISTICS OF PATIENTS WITH PSORIASIS SEEN AT THE DERMATOLOGY CLINIC OF A TERTIARY HOSPITAL IN NIGERIA: A FOUR YEAR REVIEW 2008-2012
O. A. Falodun*

P105 THE PREVALENCE AND EPIDEMIOLOGICAL CHARACTERISTICS OF PSORIASIS MORBIDITY IN LVIV REGION, UKRAINE
I. Voznyak*, T. Svyantenko

O. B. Boudghene Stambouli* and Department of Dermatology CHU University Hospital of Tlemcen (Algeria)

P107 RETROSPECTIVE STUDY ON PSORIASIS OVER A PERIOD OF 8 YEARS (2004-2010) IN ROMANIA
A. Chiriac*, A. E Chiriac, M. Moscalu, T. Pinteala, L. Foia, C. Solovan

P108 LONG-TERM EFFICACY OF JAPANESE PSORIASIS VULGARIS TREATMENTS OVER A 35-YEAR PERIOD, 1975-2010

P109 PSORIASIS: EPIDEMIOLOGICAL STUDY ON 36 CASES IN NOUAKCHOTT
K. Mariam*, A. Kane, S. Yahya, M. Ball

P110 PSORIASIS IN DERMATOLOGY PATIENTS IN PALESTINE
H. M. Arda*, M. H. Ardah

P111 CHARACTERIZATION OF THE PATIENTS FROM THE SEVERE PSORIASIS CONSULTATION AT HERMANOS AMEIJEIRAS HOSPITAL
T. Pérez Alonso*, E. S. Martinez Matute, D. J. Hidalgo González and Hermanos Ameijeiras Hospital

P112 PSORIASIS AND METABOLIC DISEASE IN THE REGION OF TLEMCE: CASE-CONTROL STUDY
D. B. Boumediene*, O. Boudghene Stambouli

P113 EPIDEMIOLOGY OF PSORIASIS IN EGYPT. AIN SHAMS UNIVERSITY EXPERIENCE
M. H. El Sayed*, M. F. Matta

P114 ARE PSORIASIS PATIENTS PRONE TO H. PYLORI INFECTION?
H. Shmuel, N. Domniz, E. Ben-Valid, J. Yahav, E. Hodak, M. David*

P115 COST EVALUATION OF TOPICAL THERAPIES FOR PATIENTS WITH PSORIASIS IN FRANCE

P116 SOCIOECONOMIC CHARACTERISTICS AMONG INDIVIDUALS WITH PLAQUE PSORIASIS: DATA FROM PATIENT REGISTRY PSOLAR
A. B. Kimball, K. Gordon, D. Pariser, B. Schenkel* and on behalf of the PSOLAR Steering Committee

P117 TRIGGERING DRUG USE IN PATIENTS WITH PSORIASIS
Z. Ogeremen*, U. Akin, M. M. Hiz, S. Cevizci

P118 DO NOT HURT YOUR SKIN: KOEBNER PHENOMENON AFTER CUPPING, A TRADITIONAL METHOD
S. Yayli*, A. Yildiz Yayli
P119 AN ANTIGEN-SPECIFIC THERAPY FOR PSORIASIS; PSORIASIS DUE TO DENTAL METAL ALLERGIES
T. Shimazu*, N. Ko, R. Ko

P120 SERUM PRO-INFLAMMATORY CYTOKINE LEVELS TNF-A, IL12, IL22 AND IL23 IN PATIENTS WITH
PSORIASIS AND METABOLIC SYNDROME
J. Brito*, A. K. SANDOVAL, M. Fafutis, G. Villanueva, A. Alvarado

P121 ROLE OF VEGF RECEPTORS IN NORMAL AND PSORIATIC KERATINOCYTES: EVIDENCE FROM
DIFFERENT UV IRRADIATION
M. Zheng*, J. Zhu

P122 INHIBITION OF KERATINOCYTE DIFFERENTIATION BY THE SYNERGISTIC EFFECT
OF PRO-INFLAMMATORY CYTOKINES IMICS PSORIASIS
V. Huguier, F. X. Bernard, J. C. Lecon, F. Morel

P123 PLASMA VITAMIN A AND E LEVELS AND ASSOCIATION OF THESE LEVELS WITH DISEASE ACTIVITY
IN PATIENTS WITH PSORIASIS
Ü. Gúl*, F. Bakır

P124 INTERACTION BETWEEN INNATE AND ADAPTIVE IMMUNE MECHANISMS IN THE
AUTOINFLAMMATORY PATHOGENESIS OF GENERALIZED PUSTULAR PSORIASIS
A. Arakawa, S. Vollmer, P. Besgen, M. Spannagl, J. C. Prinz*

P125 SERUM PROLACTIN LEVELS IN DERMATOLOGICAL DISEASES: A CASE CONTROL STUDY.
N. A. Elsherif*, A. I. El-Sherif, S. A. El-Dibany

P126 THE POSSIBLE ROLE OF PENTRAXIN-3 AND TNF ALPHA AS INFLAMMATORY MEDIATOR
IN PSORIASIS
R. Abdel Hay*, L. Rashed

P127 DETERMINATION OF THE ASSOCIATION OF THE POLYMORPHISM 3 UTR 1188 A/C OF IL12 P40
GENE (IL12B) WITH PSORIASIS VULGAR IN PATIENTS FROM WEST OF MEXICO
J. Brito*, A. K. Sandoval, M. Fafutis, G. Villanueva, A. Alvarado

P128 UNKNOUN MICROORGANISM IN PSORIASIS PATIENTS
T. Leonidze*, A. Tavarkilikadze, N. Okroscharidze

P129 THE ROLE OF TNF-ALPHA CONVERTING ENZYME IN PSORIASIS
K. Sato*, M. Takaishi, S. Sano

P130 MOLECULAR GENETIC ANALYSIS OF HLA CLASS I AND II GENES IN SPANISH PATIENTS
WITH PSORIASIS
M. L. García-Melgaress Linares*, D. Planelles Silvestre, V. Alegre de Miquel, M. Garcia Garcerá

P131 ROLE OF RAGE IN PATHOGENESIS OF PSORIASIS
A. Mezentsev*, S. Bruskin, V. Sobolev, A. Soboleva

P132 BCL2 IN MF AND PSORIASIS BEFORE AND AFTER PUVA THERAPY
A. M. Tawdy* Hani Weshay, Doaa Mahgoub

P133 CONTINUED IMPROVEMENT OF SIGNS AND SYMPTOMS IN USTEKINUMAB-TREATED PATIENTS
WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 52 RESULTS OF A PHASE 3, MULTICENTER,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
L. Puig*, A. Kavanaugh, I. B. McNees, A. B. Gottlieb, P. Rahman, C. Ritchlin, S. Li, Y. Wang,
M. K. Doyle, A. Mendelsohn and on behalf of the PSUMMIT 1 Study Group

P134 APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC
ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL (PALACE 1)

P135 VARIATIONS IN TREATMENT PATTERNS, DISEASE STATUS AND OUTCOMES AMONG PATIENTS
WITH PSORIATIC ARTHRITIS RECEIVING THEIR FIRST BIOLOGIC IN EUROPEAN UNION
S. Narayanan*, A. Basket, Y. Lu, R. Hutchings

P136 FACTORS ASSOCIATED WITH UNDIAGNOSED PSA IN PSORIASIS: ANALYSES FROM THE PREPARE
PSA STUDY

P137 DIGITAL TITANIUM – HERBST APPLIANCE AND PSORIATIC ARTHRITIS: MANDIBULAR AND CONDYLAR
GROWTH EFFECTS
U. Garagiola*, P. Cressoni, E. Del Rosso, G. Farronato
P138  PSORIATIC ARTHRITIS AND TEMPOROMANDIBULAR JOINT: HOW TO DETECT THE FIRST ARTICULAR INVOLVEMENT
U. Garagiola*, C. Bellintani, P. Cressoni, G. Farronato

P139  INFRARED THERMOGRAPHY ADDITIONAL NON-INVASIVE METHOD IN PSORIATIC ARTHRITIS DIAGNOSIS
I. Domarkaite-Jakovleve*, V. Kucinskiene, S. Valiukeviciene, V. Veikutis

P140  CHILDHOOD PSORIASIS: A 11-YEARS RETROSPECTIVE ANALYSIS IN CROATIA
R. Ceovic*, S. Murat Susic, K. Husar, M. Skerlev, K. Kostovic

P141  MANDIBULAR CHANGES IN PSORIATIC ARTHRITIS: 3D VOLUMETRIC STUDY WITH CONE BEAM COMPUTERIZED TOMOGRAPHY
U. Garagiola*, P. Cressoni, R. Soldo, G. Farronato

P142  EPISTADIOLOGY AND CLINICAL STUDY OF PEDIATRIC PSORIASIS ON BLACK SKIN IN DAKAR, SENEGAL

P143  ILVEN OR LINEAR PSORIASIS? DELVING INTO MYSTERY
K. B. Patel*

P144  PSORIASIS IN A PATIENT WITH ATOPIC DISEASE – A CASE REPORT
S. Ozanic Bulic*, L. Kohrulja

P145  ANXIETY AND DEPRESSION TEMPERAMENTS IN PATIENTS WITH PSORIASIS
N. Litaie, S. Youssef, W. Kaabi, J. El Khalifa, K. Jaber, M. R. Dhaoui, N. Doss*

P146  PSORIASIS UNCOVERED: THE RESULTS OF TWO QUANTITATIVE SURVEYS OF PSORIASIS PATIENTS IN AUSTRALIA
C. Baker*, P. Foley, A. Braue

P147  IMPACT ON QUALITY OF LIFE IN PATIENT WITH ECZEMA VERSUS PATIENT WITH PSORIASIS

P148  QUALITY OF LIFE IN PSORIASIS: AMBULATORIAL USAGE OF PDI- PSORIASIS DISABILITY INDEX VALIDATED FOR PORTUGUESE LANGUAGE
L. Azulay-Abulafia*, J. O. Lyra da Silva

P149  PSORIASIS AND FEMALE SEXUAL DYSFUNCTION: A CASE-CONTROL STUDY

P150  IMPACT OF PSORIASIS ON QUALITY OF LIFE, PRODUCTIVITY AND OCCUPATIONAL ACTIVITY: ABOUT A STUDY IN CENTRAL TUNISIA
M. Benelkahla, L. Bousofara*, M. Maoua, A. Aounallah, N. Ghariani, O. Elmaalel, M. Denguzezi, N. Mrizek, C. Belajouza, R. Nouira

P151  PREVALENCE AND CHARACTERISTICS OF CYBER PSORIATIC PATIENTS

P152  IMPACT OF DISEASE SEVERITY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN JAPANESE PATIENTS WITH PSORIASIS

P153  PREVALENCE AND CHARACTERISTICS OF PSORIATIC PATIENTS REPORTING FEELING OF STIGMATIZATION

P154  RISK FACTORS OF SEXUAL DYSFUNCTION IN PATIENTS WITH PSORIASIS

P155  CORRELATION BETWEEN PASI AND DLQI IN PATIENTS WITH PSORIASIS

P156  ASSESSMENTS OF QUALITY OF LIFE AND THERAPEUTIC EFFECTS BY BIOLOGICS TREATMENT FOR PSORIASIS VULGARIS –A COMPARISON BETWEEN BIOLOGICS AND CICLOSPORIN
P157  PSYCHODERMATOLOGY: EVALUATION OF PSYCHOSOCIAL FACTORS IN MODERATE-TO-SEVERE PSORIASIS
E. Chiticariu*, M. Mirona, C. Solovan

P158  THE POSRIASIS: THE NEED FOR CLOSE COLLABORATION BETWEEN THE PATIENT AND THE PHYSICIAN TO OPTIMIZE TREATMENT
O. B. Boudghene Stambouli* and Department of Dermatology CHU University Hospital of Tlemcen (Algeria)

P159  RETREATMENT IN PATIENTS ACHIEVING RESPONSE AFTER RELAPSE DUE TO TREATMENT INTERRUPTION: RESULTS FROM THE CRYSTEL STUDY
C. Griffiths, T. Lugur, Y. Brault, J.-M. Germain, L. Mallbris*

P160  THE RESPONSIVENESS TO CHANGE OF THE SIMPLIFIED PSORIASIS INDEX
L. Chularojanamontri*, C. E. M. Griffiths, R. J. G. Chalmers

P161  PSORIASIS SCREENING CAMPAIGN, THE MEXICAN EXPERIENCE
M. Gómez-Flores* and Mexican Foundation of Dermatology

P162  OBJECTIVE EVALUATION OF PSORIASIS SEVERITY USING A COMPUTERIZED PASI SCORING SYSTEM AND ITS SOLUBLE RECEPTOR LEVELS IN PUSTULAR PSORIASIS
A. Mohd Affandi*, S. H. Hussein, R. Baba, H. Nugraho, E. Prakasa, M. H. Ahmad Fadzil

P163  DRAMATIC DISEASE MODIFYING EFFECT OF SINGLE USTEKINUMAB INJECTION IN PSORIASIS AND PSA PATIENT. 2 YEARS FOLLOW UP CASE REPORT
K. Khobzey*, B. Lytvynenko, O. Litus

P164  COEXISTENCE OF PSORIASIS AND VITILIGO
N. N. Kogan*, O. Rosati, E. Chaparro, R. Veira, A. Crespo, S. Gusis

P165  EFFECTS OF GRANULOCYTE/MONOCYTE ADSORPTION APERHESIS THERAPY ON SERUM VEGF AND ITS SOLUBLE RECEPTOR LEVELS IN PUSTULAR PSORIASIS
M. Seishima*, T. Fujisawa, Y. Mizutani, S. Suzuki, E. Fujine

P166  FACTORS INFLUENCING ACHIEVEMENT IN NAIL PSORIASIS
H. Bouchir *, F. E. Lamchahab, A. Akazane, M. Maelainine, J. Bouhllab, M. Ait Ourhroui, B. Hassam

P167  PHOTOTHERAPY ON PSORIASIS – FIVE YEARS OF OUR WORK
N. N. Kogan*, E. Chaparro, R. Veira, A. Crespo, O. Rosati, S. Gusis

P168  VARIATIONS IN TREATMENT PATTERNS AND DISEASE SEVERITY AMONG PATIENTS WITH PSORIASIS RECEIVING THEIR FIRST BIOLOGIC IN EUROPEAN UNION
A. Franceschetti*, R. Nausedaite, S. Narayanan

P169  ESTABLISHMENT OF A NEW IN VITRO PSORIASIS MODEL FOR RNAI STUDIES

P170  RECALCITRANT GENERALIZED PUSTULAR PSORIASIS SUCCESSFULLY TREATED WITH INFLIXIMAB
A. Zaouak*, R. Bennously, H. Hammami, T. Badri, S. Fenniche, I. Mokhtar

P171  SEVER FORMS OF GERIATRIC PSORIASIS

P172  ERYTHRODERMIC PSORIASIS WITH RUPIOID LESIONS

P173  ERYTHRODERMIC PSORIASIS SUCCESSFULLY TREATED WITH ADAUMPUMAB: A CASE STUDY
D. Vidal*, L. Peramiquel, R. Olivella, M. Villar, G. Petit, A. González

P174  FOURTH-YEAR INTERIM RESULTS FROM ESPRIT, A 10-YEAR POSTMARKETING SURVEILLANCE REGISTRY OF ADAUMPUMAB FOR MODERATE TO SEVERE PSORIASIS
F. Kerdel*, D. Thaçi, M. Bereswill, D. A. Williams

P175  METHOTREXATE AND LIVER FIBROSIS – A SURVEY OF 38 PSORIATIC PATIENTS
G. Tauber*, L. Pavlovsky, M. David, K. Shor-Steinfeld, E. Hodak

P176  GEOGRAPHIC TONGUE AND FISSURED TONGUE IN 348 PATIENTS WITH PSORIASIS: CORRELATION WITH DISEASE SEVERITY

P177  PSORIASIS ASSOCIATED WITH HEPATITIS C
B. Dahmani*, O. Boudghene Stambouli

P178  PROFILE OF EPIDERMAL MICROFLORA IN PSORIATIC PATIENTS
H. Astsaturov*, O. Syzon
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P179</td>
<td>PSORIASIS AND AIDS: THE CUBAN EXPERIENCE</td>
<td>O. A. Blanco*, D. Verdasquera, V. Capó, M. E. Fiqueredo, B. Mantecón, B. L. Blanco and Institute of Tropical Medicine “Pedro Kourí”, La Habana, CUBA</td>
</tr>
<tr>
<td>P181</td>
<td>ACUTE TRANSVERSE MYELITIS DURING TREATMENT FOR SEVERE PLAQUE PSORIASIS WITH ETANCERCEPT: A CASE REPORT</td>
<td>J. Escalas*, N. Knöpfel, C. Calles, A. Bauzá, A. Martin-Santiago</td>
</tr>
<tr>
<td>P182</td>
<td>“TO KILL TWO BIRDS WITH ONE STONE”: RIFAMPICIN CLEARS PSORIASIS IN QFT-POSITIVE PATIENTS</td>
<td>I. Grozdev*, N. Tsankov</td>
</tr>
<tr>
<td>P183</td>
<td>CLINICAL AND DIAGNOSTIC SIGNS OF PSORIATIC ERYthroDERMA</td>
<td>U. P. Adaskevich*</td>
</tr>
<tr>
<td>P184</td>
<td>IS RESTLESS LEGS SYNDROME ASSOCIATED WITH PSORIASIS?</td>
<td>A. Bilgic*, N. Samanci-Karaman, A. Akman-Karaka, E. Yilmaz, E. Alpsoy</td>
</tr>
<tr>
<td>P185</td>
<td>IL-6 AND TNF-ALPHA POLYMORPHISMS IN PORTUGESE PSORIATIC PATIENTS</td>
<td>J. P. Ferreira*, T. Torres, C. Carvalho, A. Bettencourt, B. Leal, C. Vasconcelos, P. P. Costa, M. Selores, B. M. Silva</td>
</tr>
<tr>
<td>P186</td>
<td>PECULIARITIES OF THE PSORIATIC ONYCHODYSTROPHY</td>
<td>E. Topychkanova, N. Filimonkova*, V. Baitychakov</td>
</tr>
<tr>
<td>P188</td>
<td>PSORIASIS RESULTING FROM PEGYLATED INTERFERON ALPHA AND RIBAVIRIN TREATMENT OF CHRONIC HEPATITIS C</td>
<td>W. Kaabi, S. Youssef, N. Litaieim, J. El Khalifa, K. Jaber, M. R. Dhaoui, N. Doss*</td>
</tr>
<tr>
<td>P189</td>
<td>CLINICAL AND SOCIODEMOGRAPHIC FACTORS AFFECTING SCALP PSORIASIS: A COMPERATIVE CASE-SERIES STUDY</td>
<td>A. Akman-Karakas*, E. Yilmaz, E. Alpsoy</td>
</tr>
<tr>
<td>P190</td>
<td>APOE ISOFORMS IN PATIENTS WITH PSORIASIS</td>
<td>J. C. P. Ferreira*, T. Torres, C. A. Carvalho, A. Bettencourt, B. Leal, C. Vasconcelos, P. P. Costa, M. Selores, B. M. Silva</td>
</tr>
<tr>
<td>P191</td>
<td>STATE OF VACCINATIONS IN PSORIASIS PATIENTS</td>
<td>M. Sticherling*, E. Tasler-Salloum</td>
</tr>
<tr>
<td>P192</td>
<td>MANAGEMENT OF PSORIASIS AMONG MILITARIES: OUR EXPERIENCE IN MILITARY HOSPITAL OF TUNIS</td>
<td>J. El Khalifa, J. El Khalifa, K. Jaber, N. Litaieim, W. Kaabi, S. Youssef, R. Dhaoui, N. Doss*</td>
</tr>
<tr>
<td>P193</td>
<td>METHOTREXATE AND PSORIASIS: LESS PAIN FOR MORE GAIN</td>
<td>J. El Khalifa, W. Kaabi, S. Youssef, N. Litaieim, K. Jaber, R. Dhaoui, N. Doss*</td>
</tr>
<tr>
<td>P194</td>
<td>PARADOXAL PSORIASIFORM ERUPTIONS AFTER THE ANTI-TNF ALPHA THERAPY IN EIGHT PATIENTS</td>
<td>S. Urbancsek*, P. Kozub, M. Kuklova-Bielikova</td>
</tr>
<tr>
<td>P195</td>
<td>FOURNIER’S GANGRENE IN A PATIENT TREATED WITH ETANCERCEPT: A REPORT OF A CASE</td>
<td>H. Sahel* and N Nait Saada, F Otmane, B Bouadjar</td>
</tr>
</tbody>
</table>
Lilly, Major Corporate Partner, welcomes delegates to the 4th Congress of The Psoriasis International Network.

*Lilly Satellite Symposium to be held Sat. Jul. 6, 2013 12:30–2pm.*
Welcome to Paris!

Venue & Dates
The 4th International Congress of Psoriasis will be held from Thursday 4 to Saturday 6 July 2013 in the Palais des Congrès, in Paris.

Paris can easily be reached by plane, train or car, as it is located crossroad of Europe. It is served by two international airports and a very convenient railway system. The shuttle buses from Charles de Gaulle or Orly airports arrive downtown.

The Palais des Congrès is easily accessible: by car (Parking Porte Maillot under the Convention Centre), by local city bus (lines 82 - 73 - 43 - 244 PC) or by metro (line 1) or RER (Paris Suburban Express Metropolitan Network, line C). The station is called “Porte Maillot”.

Official language
Organized by an International Scientific Society, all presentations will be given in English.

Congress office
Before and after the meeting:
PSORIASIS 2013 – MCI
24 rue Chauchat
75009 Paris – France
Tel.: 33 (0) 1 53 85 82 59
Fax: 33 (0) 1 53 85 82 83
E-mail: ps2013@mci-group.com
Web: www.pso2013.com

On-site Secretariat: (Tentative Opening hours)
- Thursday, July 4, 2013 : 08:30am – 06:30pm
- Friday, July 5, 2013 : 07:30am – 06:00pm
- Saturday, July 6, 2013 : 08:00am – 06:30pm

The Congress documentation will be available there for pre-registered delegates and for anyone wishing to register on site.
● **Badges**
A name badge will be provided with your registration documents on site (and not mailed out prior to the congress).

● **Climate and clothing**
The weather in Paris in July is usually hot and sunny with daily temperatures ranging from 20°C to 25°. Night temperatures are usually mild.

● **CME Credits**
Continuing Medical Education credits will be offered by Medical Academies and Scientific Societies from all over the world. Participants may register for CME credits in their own countries. Certificate of attendance will be delivered on site. More information will be posted on the Congress website.

● **Currency exchange**
ALL RATES given in the programme are in EUROS: €

● **Electricity**
Electricity used in France is 220 Volts; its frequency is 50 Hz and the plugs have two male contact points. Plan to bring a transformer for your electrical or electronic equipment using different voltage.

● **Exhibition & sponsorship**
A scientific and technical Showcase will be open on Thursday afternoon, Friday and Saturday to pharmaceutical companies, manufacturers of materials and equipment and scientific publishers. It will be held in the Congress Venue.

As a pharmaceutical company or manufacturer, you may want to sponsor a session within the core programme or organize a satellite meeting.

For exhibit or sponsorship, you can contact any time the Congress Office:

pso2013EXH@mci-group.com

● **Insurance & Liability**
The Organizers will accept no liability for personal injuries sustained by or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress or during all events.

Participants are strongly recommended to seek insurance coverage for health and accident, lost luggage and trip cancellation.

● **Lunches & Break**
Lunches are NOT included in the registration fees but sandwiches and snacks can be purchased at all times within the premises of the Palais des Congrès.

● **Telephones**
For international calls to France, dial the international code followed by 33 and the correspondent’s number without the “0”.

● **Visa & Passeports**
Every person entering France should be in possession of a valid passport and/or identification card. Some countries require a Visa.

Please contact the nearest French Embassy or Consulate to your home for further information.
Registration procedure

All participants must be registered and are urged to register in advance. You can register by submitting registration and payment via the Congress website: www.pso2013.com (and follow the instructions).

You can either download the registration form on PDF format and send it along with your payment to the Congress Office OR register online on a secure server in paying with your credit card or bank transfer. Registration per phone will not be processed. Registrants will receive confirmation by way of an invoice and acknowledgement letter which will be mailed and which will recall all the information given on the registration form, including the amount of Value Added Tax (VAT) paid and all other requests. This confirmation letter should be presented upon arrival at the Pre-registration Counter.

<table>
<thead>
<tr>
<th></th>
<th>Until March 20, 2013</th>
<th>After March 20, 2013</th>
<th>On-site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>560€</td>
<td>630€</td>
<td>710€</td>
</tr>
<tr>
<td>Students*</td>
<td>200€</td>
<td>200€</td>
<td>200€</td>
</tr>
<tr>
<td>Patient Association member**</td>
<td>Free</td>
<td>Free</td>
<td>Free</td>
</tr>
</tbody>
</table>

All indicate rates above include a VAT of 19.6% at current rate at the day of printing.

* Please provide certificate
** Please provide a copy of a valid membership card.

● Delegates’ registration fees include

- Admission to all congress sessions, poster areas and technical exhibition
- Congress documents (final programme, abstracts book, congress bag)
- Access to the Courses on Thursday, July 4, 10:00-12:00 – On-line reservation mandatory
- Networking Reception on Thursday, July 4

● Terms of payment

- The “Fondation René Touraine pour la Dermatologie”, (domiciliée Hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris) has given mandate to MCI for the organization of the 4th INTERNATIONAL CONGRESS ON PSORIASIS 2013 and therefore to act and receive the fees on its behalf.
- Payment must be sent to the Congress Office in EUROS (£)
  - by cheque payable in France to the order of PSO 2013 - MCI
  - by Credit card : VISA, EURO/MASTER CARD or AMEX only (NO other cards accepted)
  - by bank transfer to the order of PSO 2013 – MCI to CREDIT LYONNAIS – Paris SDC Ouest 19, boulevard des Italiens 75002 Paris – France


Copy of the bank transfer must be attached to the registration form. Do NOT forget to give the name of the person you are paying for, on the bank transfer order.

● Name changes / modifications

A processing fee of 30€ will be charged for changes in registration except for name substitutions which will be treated as new registrations.

● Cancellation policy for individual registration & reservations

All cancellations must be notified in writing (by mail or e-mail) to the Congress Office according to the following conditions and reimbursement will be processed AFTER the Congress. Requests for refunds made after September 1, 2013 will not be considered:

- Up to March 20, 2013: 100€ will be withheld for administrative fee,
- Cancellations between March 21 and May 1, 2013: reimbursement of 50% of the fees paid,
- After May 1, 2013: no refund.
Accommodation

Hotel rooms at special Congress rates are being held for congress participants and their families in various hotels of different categories in the vicinity of the Congress Venue. But there will be no shuttle services provided by the congress between the congress hotels and the Palais des Congrès.

To make a reservation, visit the Congress website: www.pso2013.com. A PAYMENT of the FULL STAY will be requested for all hotel reservations. It will be automatically deducted from the total amount of your hotel bill when leaving.

- **Room rates**
  
  All rates are indicated in euros, per night and per room. Reservations must be made through the Congress Office to guarantee the indicated rates negotiated for the Congress. Unless otherwise indicated, most of the rates do not include breakfast.

  **Do not forget:**
  
  - If you decide to postpone your stay at the last minute, the rooms will be kept by the hotels according to the amount of the payment received.
  - If you are delayed, think of informing the hotel.

  - No reservation will be made without the requested deposit.
  
  For University housing, please consult the web site.

- **Cancellation conditions for hotel reservations**

  All cancellations must be notified in writing (by mail or fax BUT NOT email) to the Congress Office according to the following conditions:

  - Cancellations between March 21 and May 2, 2013: 50% of the payment will be withheld
  - After May 2, 2013: no refund.

<table>
<thead>
<tr>
<th>★</th>
<th>Hotels</th>
<th>Type of room</th>
<th>Single room</th>
<th>Double room</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1</td>
<td>Méridien Etoile</td>
<td>Deluxe</td>
<td>239€</td>
<td>259€</td>
</tr>
<tr>
<td>H2</td>
<td>Concorde La Fayette</td>
<td>Classic</td>
<td>200€</td>
<td>220€</td>
</tr>
<tr>
<td>H3</td>
<td>Magellan</td>
<td>Standard</td>
<td>129€</td>
<td>153€</td>
</tr>
<tr>
<td>H4</td>
<td>Résidence Impériale</td>
<td>Superiors</td>
<td>195€</td>
<td>210€</td>
</tr>
<tr>
<td>H5</td>
<td>Best Western Star Champs Elysées</td>
<td>Classic</td>
<td>198€</td>
<td>241€</td>
</tr>
<tr>
<td>H6</td>
<td>Fertel Maillot</td>
<td>Standard</td>
<td>140€</td>
<td>155€</td>
</tr>
</tbody>
</table>

The rates are breakfast and taxes included.
Sponsors acknowledgements

The Organising Committee would like to thank the following companies for their support:

### MAJOR CORPORATE PARTNERS

- Abbvie
- Lilly
- Pfizer

### CORPORATE PARTNER

- Celgene

### CORPORATE SUPPORTERS

- Genevrier/IBSA
- Janssen
- MSD